基于血清药物化学与多组学揭示常麻熄风片治疗抽动障碍的活性成分与机制
该研究整合血清药物化学、网络药理学、肠道菌群与转录组学,探究常麻熄风片对IDPN诱导的抽动障碍小鼠模型的作用机制。共鉴定15种入血成分,发现其通过调节肠道菌群、抑制TLRs/NF-κB信号通路,改善抽动样行为及神经递质失衡。
要点
- 常麻熄风片可改善IDPN诱导的抽动障碍小鼠抽动样行为评分
- 其机制涉及调节肠道菌群组成及抑制纹状体TLRs/NF-κB通路
- 没食子酸、儿茶素、西伯利亚远志糖A5可能为活性成分
核心结论
- 常麻熄风片可能通过调节肠道菌群和抑制TLRs/NF-κB信号通路缓解抽动障碍症状。
- 没食子酸、儿茶素、西伯利亚远志糖A5可能是常麻熄风片治疗抽动障碍的活性成分。
研究设计与样本
- 研究采用血清药物化学和网络药理学预测常麻熄风片的活性成分、靶点与通路。
- 随后基于IDPN(350 mg/kg)诱导的抽动障碍小鼠模型,整合行为学评估、ELISA、HE染色、免疫组化、16S rDNA测序、转录组测序和Western blot技术进行验证。
主要发现
- 在抽动障碍小鼠血清中鉴定出15种常麻熄风片入血成分。
- 网络药理学分析提示Toll样受体信号通路、PI3K-Akt信号通路和NF-κB信号通路为其关键通路。
- 常麻熄风片干预显著改善小鼠抽动样行为评分,降低多巴胺、高香草酸和去甲肾上腺素水平,并提高5-羟色胺水平。
- 免疫组化显示常麻熄风片显著抑制纹状体DRD1和DRD2表达,同时激活DAT和GABAR表达。
- 常麻熄风片上调紧密连接蛋白ZO-1、Occludin和Claudin-1表达以改善肠道屏障功能,并改变肠道菌群组成。
关键数值与推荐
- 常麻熄风片治疗显著降低Alloprevotella丰度,增加Desulfovibrio、Lactobacillus、Bacteroides、Dubosiella和Muribaculum丰度。
- 转录组测序和基因富集分析表明常麻熄风片主要调控NF-κB通路。
- 常麻熄风片显著下调纹状体中TLR2、TLR4、p-p65、p-IKBα和p-IKKβ表达。
临床怎么用
- 该研究为常麻熄风片治疗儿童抽动障碍提供了实验依据,提示其作用与调节肠道菌群及TLRs/NF-κB通路相关。
- 临床可关注常麻熄风片对抽动障碍患者神经递质平衡及肠道屏障功能的潜在影响。
局限性
- 研究仅基于IDPN诱导的小鼠模型,结果外推至儿童抽动障碍患者需谨慎。
- 活性成分与具体靶点间的直接结合作用尚未通过实验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Tourette syndrome (TS) is a chronic neurodevelopmental disorder in children characterized by persistent motor and vocal tics, which significantly impairs the quality of life of patients. Changma Xifeng Tablet (CMXF), a traditional Chinese medicine formulation, has demonstrated efficacy in alleviating TS symptoms in pediatric patients. Nevertheless, its bioactive components and precise mechanisms remain to be elucidated. AIM OF THE STUDY: This research aims to investigate the active ingredients and pharmacological mechanism of CMXF on 3,3'-iminodipropionitrile (IDPN)-induced TS. METHODS: Serum pharmacochemistry and network pharmacology were used to identify the active ingredients and possible targets and pathway of CMXF in the treatment of TS. Subsequently, based on the IDPN (350 mg/kg)-induced TS mice model, the behavioral assessment, ELISA, hematoxylin-eosin, immunohistochemical (IHC), 16 S rDNA, transcriptome sequencing, and western blotting (WB) techniques were integrated to reveal the mechanisms of CMXF for TS treatment. RESULTS: A total of 15 compounds absorbed in vivo were identified in TS mice serum. Through network pharmacology analysis, Toll-like receptor (TLR) signaling pathway, PI3K-Akt signaling pathway, and NF-κB signaling pathway, were identified as key signaling pathways of CMXF in the treatment of TS. Additionally, the in vivo results indicated that CMXF intervention significantly ameliorated the tic-like behavior score of mice, reduced the levels of excitatory neurotransmitters, such as dopamin, homovanillic acid, and norepinephrine, and increased the levels of inhibitory neurotransmitter 5-Hydroxytryptamine. Besides, IHC analysis revealed that CMXF significantly inhibited the expression of dopamine receptors (DRD1 and DRD2), while activating the expression of DAT and GABAR in the striatum. Moreover, CMXF improved intestinal barrier function by upregulating the expression of tight junction proteins (ZO-1, Occludin, and Claudin-1), and altered the composition of the gut microbiota. Specifically, CMXF treatment significantly reduced the abundance of Alloprevotella, while increased the abundance of Desulfovibrio, Lactobacillus, Bacteroides, Dubosiella and Muribaculum. Furthermore, transcriptome sequencing and gene enrichment analysis indicated that CMXF primarily modulated the NF-κB pathway. CMXF could significantly downregulated the expression of TLR2, TLR4, p-p65, p-IKBα and p-IKKβ in the striatum. CONCLUSION: Our results suggested that CMXF could alleviate TS symptoms by regulating gut microbiota and inhibiting the TLRs/NF-κB signaling pathway. Gallic acid, catechin, sibiricose A5 may be the active ingredients in CMXF involved in the treatment of TS.
引用
- Zhu C, Shi Y, Zhou Z, et al. Integrating serum pharmacochemistry, network pharmacology, gut microbiota and transcriptomic strategies to reveal the active ingredients and mechanism of Changma Xifeng tablet in the treatment of tourette syndrome. J Ethnopharmacol. 2025. PMID: 41173081. doi:10.1016/j.jep.2025.120830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。